Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
A randomized multi-center phase II trial of nab-paclitaxel in combination with gemcitabine verus S1 with gemcitabine as first-Line treatment for locally advanced or metastatic pancreatic cancer
Pancreatic Cancer|Nab-paclitaxel|Gemcitabine|S1
DRUG: S1 or Gemcitabine
PFS, progression-free survival, 6 month
OS, overall survival, 1 year|ORR, objective response rate, 6 month|DCR, CR+PR+SD was defined as disease control rate (DCR), 6 month|Safety profile :Adverse events of nab-Paclitaxel plus S-1, Adverse events of nab-Paclitaxel plus S-1, 1 year
A Phase II, open-label randomized, multicenter trial to compare nab-paclitaxel in combination with gemcitabine verus S1 with gemcitabine with respect to overall survival, objective tumor response rate and Progression Free Survival (PFS) in patients diagnosed with locally advanced or metastatic adenocarcinoma of the pancreas.